OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Arkenau Discusses AZD4547 and FGFR Amplification in Advanced Solid Tumors

August 28th 2014

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

August 28th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease

August 26th 2014

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).

Dr. Flinn Discusses IPI-145 as Potential Treatment for Hematologic Malignancies

August 26th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

Dr. Flynn on Obinutuzumab for the Treatment of CLL

August 25th 2014

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Dr. Parsons Discusses the Link Between Exercise and Bladder Cancer Risk

August 25th 2014

J. Kellogg Parsons, MD, associate professor of surgery (urology), University of California, San Diego, discusses modifiable lifestyle factors associated with bladder cancer.

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

August 22nd 2014

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

August 21st 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

Dr. Herbst Discusses New Immunotherapy Agents for Lung Cancer

August 20th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRC

August 19th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

August 18th 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Dr. Wakelee on Continued Maintenance in Lung Cancer

August 15th 2014

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses continued maintenance therapy in lung cancer.

Dr. Venook Discusses the Results of the 80405 Trial

August 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

Dr. Stuart on Risks of Phase I Liver Dysfunction Studies

August 14th 2014

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

August 14th 2014

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

Dr. Allen Discusses CO-1686 as a Treatment for Lung Cancer

August 13th 2014

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Dr. Jabbari on the Potential for Implantable Cardiac Devices to Malfunction Following RT

August 12th 2014

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.

Dr. Tempero Discusses Screening for Pancreatic Cancer

August 12th 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses screening tools used for patients at high risk for pancreatic cancer.

Dr. Brufsky Discusses Future Research into Bisphosphonates

August 11th 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

Dr. Gandara Discusses Third-Generation EGFR TKIs

August 11th 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.